2025
Triage Plus Price Set to Lift Pacific Edge's Economics
Pacific Edge notes today that the draft ‘Gapfill’ prices for Cxbladder Triage Plus2 have been published by the US Centers for Medicare & Medicaid Services (CMS) proposing a draft price for the test of US$1,018.44. [read more]
Medicare LCD Effective; Pacific Edge Seeks Recoverage
Pacific Edge notes the ‘Genetic Testing in Oncology: Specific Tests’ (L39365) Local Coverage Determination became effective on 24 April 2025 in the US, halting Medicare coverage of Cxbladder tests. [read more]
Cxbladder's Clinical Utility in Focus at AUA 2025
Recognition of Cxbladder’s clinical and economic value in evaluating patients presenting with hematuria is set to gain momentum at the American Urological Association’s (AUA) Annual Meeting, April 26–29 in Las Vegas. [read more]
Q4 25 Cxbladder Volumes Rise and Key Metrics Improve
Pacific Edge today announces tests processed at its laboratories in Q4 25 improved 6.8% on the prior quarter (Q3 25), lifted by increased adoption in the US. [read more]
Cxbladder Guideline Inclusion to Feature at SESAUA
The inclusion of Cxbladder Triage in a February 2025 amendment to the American Urology Association (AUA) Microhematuria Guideline is set to headline a symposium at the Annual Meeting of the Southeastern Section of the AUA (SESAUA) to be held 12-15 March in Nashville, Tennessee. [read more]
Cxbladder Incorporated into AUA Clinical Guideline
Pacific Edge today announces the American Urological Association (AUA) has included Cxbladder Triage in an amendment to its clinical guideline for the management of patients presenting with microhematuria. [read more]
Pacific Edge Releases Medicare LCD Evidence Rebuttal
Pacific Edge has today released a detailed rebuttal of the evidentiary review used to support the finalization of the ‘Genetic Testing in Oncology: Specific Tests’ (L39365 ) Local Coverage Determination (LCD) that is expected to come into effect on 24 April 2025. [read more]
Medicare LCD Effective Date Extended to 24 April 2025
Pacific Edge advises the date at which the ‘Genetic Testing in Oncology: Specific Tests’ (L39365) Local Coverage Determination (LCD) comes into effect has been extended by two months until Thursday 24 April 2025 (US time) from the original date of Sunday 23 February (US time). [read more]
Pacific Edge Releases Quarterly Volumes for Q3 FY25
Pacific Edge today announces tests processed at its laboratories in the three months to the end of December 2024 (Q3 25) were steady on the prior quarter (Q2 25). [read more]
Novitas Finalizes Non-Coverage Determination
Pacific Edge today notes that Novitas, the MAC with jurisdiction for our US laboratory, on Thursday 9 January 2025 finalized a non-coverage determination that would end reimbursement for Cxbladder Triage, Detect and Monitor by Medicare. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.
